Listed

Bone Biologics Corp

BBLGNasdaqCIK 1419554HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$666.3k, Q3 FY2026
Net income−$617.7k, Q3 FY2026
Bone Biologics Corp, income statement, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Gross profit$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k447Research and development, Q4 FY2023, three months to 2023-12-31$447.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-26, accession 0001493152-25-008383. Derived: 12-month figure less the 9-month figure.Report this figure246Research and development, Q1 FY2024, three months to 2024-03-31$245.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure350Research and development, Q2 FY2024, three months to 2024-06-30$350.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure430Research and development, Q3 FY2024, three months to 2024-09-30$429.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure1,105Research and development, Q4 FY2024, three months to 2024-12-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-02, accession 0001493152-26-008564. Derived: 12-month figure less the 9-month figure.Report this figure424Research and development, Q1 FY2025, three months to 2025-03-31$423.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure192Research and development, Q2 FY2025, three months to 2025-06-30$191.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure188Research and development, Q3 FY2025, three months to 2025-09-30$187.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure257Research and development, Q4 FY2025, three months to 2025-12-31$257.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-02, accession 0001493152-26-008564. Derived: 12-month figure less the 9-month figure.Report this figure142Research and development, Q1 FY2026, three months to 2026-03-31$141.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure309Research and development, Q2 FY2026, three months to 2026-06-30$308.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure243Research and development, Q3 FY2026, three months to 2026-09-30$242.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Operating income$k(1,160)Operating income, Q4 FY2023, three months to 2023-12-31−$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-26, accession 0001493152-25-008383. Derived: 12-month figure less the 9-month figure.Report this figure(904)Operating income, Q1 FY2024, three months to 2024-03-31−$903.5k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure(810)Operating income, Q2 FY2024, three months to 2024-06-30−$809.7k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure(951)Operating income, Q3 FY2024, three months to 2024-09-30−$951.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure(1,555)Operating income, Q4 FY2024, three months to 2024-12-31−$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-02, accession 0001493152-26-008564. Derived: 12-month figure less the 9-month figure.Report this figure(1,038)Operating income, Q1 FY2025, three months to 2025-03-31−$1.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure(748)Operating income, Q2 FY2025, three months to 2025-06-30−$748.1k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure(715)Operating income, Q3 FY2025, three months to 2025-09-30−$715.3k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure(733)Operating income, Q4 FY2025, three months to 2025-12-31−$733.1k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-02, accession 0001493152-26-008564. Derived: 12-month figure less the 9-month figure.Report this figure(805)Operating income, Q1 FY2026, three months to 2026-03-31−$805.1k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure(808)Operating income, Q2 FY2026, three months to 2026-06-30−$808.1k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure(666)Operating income, Q3 FY2026, three months to 2026-09-30−$666.3k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Interest expense$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(1,550)Net income, Q4 FY2023, three months to 2023-12-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-26, accession 0001493152-25-008383. Derived: 12-month figure less the 9-month figure.Report this figure(866)Net income, Q1 FY2024, three months to 2024-03-31−$866.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure(784)Net income, Q2 FY2024, three months to 2024-06-30−$783.7k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure(941)Net income, Q3 FY2024, three months to 2024-09-30−$941.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure(1,522)Net income, Q4 FY2024, three months to 2024-12-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-02, accession 0001493152-26-008564. Derived: 12-month figure less the 9-month figure.Report this figure(1,017)Net income, Q1 FY2025, three months to 2025-03-31−$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure(741)Net income, Q2 FY2025, three months to 2025-06-30−$740.5k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure(667)Net income, Q3 FY2025, three months to 2025-09-30−$666.7k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure(685)Net income, Q4 FY2025, three months to 2025-12-31−$684.6k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-02, accession 0001493152-26-008564. Derived: 12-month figure less the 9-month figure.Report this figure(766)Net income, Q1 FY2026, three months to 2026-03-31−$766.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure(774)Net income, Q2 FY2026, three months to 2026-06-30−$773.7k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure(618)Net income, Q3 FY2026, three months to 2026-09-30−$617.7k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Diluted EPS$ per sharenot reported(1.31)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure(4.02)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$4.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure(14.21)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$14.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figurenot reported(1.92)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure(1.33)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure(0.37)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figurenot reported(0.43)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure(0.43)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure(0.17)Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Basic EPS$ per sharenot reported(1.31)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure(4.02)Basic EPS, Q2 FY2024, three months to 2024-06-30−$4.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure(14.21)Basic EPS, Q3 FY2024, three months to 2024-09-30−$14.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figurenot reported(1.92)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.92 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure(1.33)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure(0.37)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figurenot reported(0.43)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure(0.43)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure(0.17)Basic EPS, Q3 FY2026, three months to 2026-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure

Balance sheet

Cash and equivalents$6.1m, Q3 FY2026
Shareholders' equity$6.0m, Q3 FY2026
Bone Biologics Corp, balance sheet, quarterly
Line itemUnitFY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Cash and equivalents$k3,027Cash and equivalents, FY2023, at 2023-12-31$3.0m. XBRL concept us-gaap:Cash. 10-K filed 2025-02-26, accession 0001493152-25-008383.Report this figure3,228Cash and equivalents, Q1 FY2024, at 2024-03-31$3.2m. XBRL concept us-gaap:Cash. 10-Q filed 2024-05-14, accession 0001493152-24-019271.Report this figure2,332Cash and equivalents, Q2 FY2024, at 2024-06-30$2.3m. XBRL concept us-gaap:Cash. 10-Q filed 2024-08-09, accession 0001493152-24-030982.Report this figure3,566Cash and equivalents, Q3 FY2024, at 2024-09-30$3.6m. XBRL concept us-gaap:Cash. 10-Q filed 2024-11-14, accession 0001493152-24-046020.Report this figure3,325Cash and equivalents, FY2024, at 2024-12-31$3.3m. XBRL concept us-gaap:Cash. 10-K filed 2026-03-02, accession 0001493152-26-008564.Report this figure2,747Cash and equivalents, Q1 FY2025, at 2025-03-31$2.7m. XBRL concept us-gaap:Cash. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure6,640Cash and equivalents, Q2 FY2025, at 2025-06-30$6.6m. XBRL concept us-gaap:Cash. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure6,049Cash and equivalents, Q3 FY2025, at 2025-09-30$6.0m. XBRL concept us-gaap:Cash. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure5,334Cash and equivalents, FY2025, at 2025-12-31$5.3m. XBRL concept us-gaap:Cash. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure4,530Cash and equivalents, Q1 FY2026, at 2026-03-31$4.5m. XBRL concept us-gaap:Cash. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure4,032Cash and equivalents, Q2 FY2026, at 2026-06-30$4.0m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure6,088Cash and equivalents, Q3 FY2026, at 2026-09-30$6.1m. XBRL concept us-gaap:Cash. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Current assets$k3,738Current assets, FY2023, at 2023-12-31$3.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-26, accession 0001493152-25-008383.Report this figure3,840Current assets, Q1 FY2024, at 2024-03-31$3.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0001493152-24-019271.Report this figure3,193Current assets, Q2 FY2024, at 2024-06-30$3.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-09, accession 0001493152-24-030982.Report this figure4,066Current assets, Q3 FY2024, at 2024-09-30$4.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001493152-24-046020.Report this figure3,861Current assets, FY2024, at 2024-12-31$3.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-02, accession 0001493152-26-008564.Report this figure3,162Current assets, Q1 FY2025, at 2025-03-31$3.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure7,002Current assets, Q2 FY2025, at 2025-06-30$7.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure6,351Current assets, Q3 FY2025, at 2025-09-30$6.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure5,796Current assets, FY2025, at 2025-12-31$5.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure4,979Current assets, Q1 FY2026, at 2026-03-31$5.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure4,437Current assets, Q2 FY2026, at 2026-06-30$4.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure6,432Current assets, Q3 FY2026, at 2026-09-30$6.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Total assets$k3,738Total assets, FY2023, at 2023-12-31$3.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-26, accession 0001493152-25-008383.Report this figure3,840Total assets, Q1 FY2024, at 2024-03-31$3.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0001493152-24-019271.Report this figure3,193Total assets, Q2 FY2024, at 2024-06-30$3.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-09, accession 0001493152-24-030982.Report this figure4,066Total assets, Q3 FY2024, at 2024-09-30$4.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001493152-24-046020.Report this figure3,861Total assets, FY2024, at 2024-12-31$3.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-02, accession 0001493152-26-008564.Report this figure3,162Total assets, Q1 FY2025, at 2025-03-31$3.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure7,002Total assets, Q2 FY2025, at 2025-06-30$7.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure6,351Total assets, Q3 FY2025, at 2025-09-30$6.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure5,796Total assets, FY2025, at 2025-12-31$5.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure4,979Total assets, Q1 FY2026, at 2026-03-31$5.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure4,437Total assets, Q2 FY2026, at 2026-06-30$4.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure6,432Total assets, Q3 FY2026, at 2026-09-30$6.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Current liabilities$k831Current liabilities, FY2023, at 2023-12-31$831.4k. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-26, accession 0001493152-25-008383.Report this figure165Current liabilities, Q1 FY2024, at 2024-03-31$164.6k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0001493152-24-019271.Report this figure285Current liabilities, Q2 FY2024, at 2024-06-30$284.5k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-09, accession 0001493152-24-030982.Report this figure273Current liabilities, Q3 FY2024, at 2024-09-30$273.4k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001493152-24-046020.Report this figure378Current liabilities, FY2024, at 2024-12-31$377.7k. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-02, accession 0001493152-26-008564.Report this figure251Current liabilities, Q1 FY2025, at 2025-03-31$251.2k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure406Current liabilities, Q2 FY2025, at 2025-06-30$406.1k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure334Current liabilities, Q3 FY2025, at 2025-09-30$334.3k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure419Current liabilities, FY2025, at 2025-12-31$418.6k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure309Current liabilities, Q1 FY2026, at 2026-03-31$309.4k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure512Current liabilities, Q2 FY2026, at 2026-06-30$512.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure481Current liabilities, Q3 FY2026, at 2026-09-30$480.8k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Total liabilities$k831Total liabilities, FY2023, at 2023-12-31$831.4k. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-26, accession 0001493152-25-008383.Report this figure165Total liabilities, Q1 FY2024, at 2024-03-31$164.6k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0001493152-24-019271.Report this figure285Total liabilities, Q2 FY2024, at 2024-06-30$284.5k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-09, accession 0001493152-24-030982.Report this figure273Total liabilities, Q3 FY2024, at 2024-09-30$273.4k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001493152-24-046020.Report this figure378Total liabilities, FY2024, at 2024-12-31$377.7k. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-02, accession 0001493152-26-008564.Report this figure251Total liabilities, Q1 FY2025, at 2025-03-31$251.2k. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure406Total liabilities, Q2 FY2025, at 2025-06-30$406.1k. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure334Total liabilities, Q3 FY2025, at 2025-09-30$334.3k. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure419Total liabilities, FY2025, at 2025-12-31$418.6k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure309Total liabilities, Q1 FY2026, at 2026-03-31$309.4k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure512Total liabilities, Q2 FY2026, at 2026-06-30$512.0k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure481Total liabilities, Q3 FY2026, at 2026-09-30$480.8k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure
Shareholders' equity$k2,906Shareholders' equity, FY2023, at 2023-12-31$2.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-02, accession 0001493152-26-008564.Report this figure3,675Shareholders' equity, Q1 FY2024, at 2024-03-31$3.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure2,909Shareholders' equity, Q2 FY2024, at 2024-06-30$2.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure3,792Shareholders' equity, Q3 FY2024, at 2024-09-30$3.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure3,484Shareholders' equity, FY2024, at 2024-12-31$3.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure2,911Shareholders' equity, Q1 FY2025, at 2025-03-31$2.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure6,596Shareholders' equity, Q2 FY2025, at 2025-06-30$6.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure6,017Shareholders' equity, Q3 FY2025, at 2025-09-30$6.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure5,378Shareholders' equity, FY2025, at 2025-12-31$5.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure4,670Shareholders' equity, Q1 FY2026, at 2026-03-31$4.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure3,925Shareholders' equity, Q2 FY2026, at 2026-06-30$3.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure5,952Shareholders' equity, Q3 FY2026, at 2026-09-30$6.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure

Cash flow

Operating cash flow−$532.3k, Q3 FY2026
Bone Biologics Corp, cash flow, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Operating cash flow$k(2,018)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-26, accession 0001493152-25-008383. Derived: 12-month figure less the 9-month figure.Report this figure(1,303)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure(896)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$895.9k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001493152-25-011993. Derived: 6-month figure less the 3-month figure.Report this figure(572)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$572.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001493152-25-023563. Derived: 9-month figure less the 6-month figure.Report this figure(1,353)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-02, accession 0001493152-26-008564. Derived: 12-month figure less the 9-month figure.Report this figure(926)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$926.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure(459)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$458.9k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001493152-26-038482. Derived: 6-month figure less the 3-month figure.Report this figure(591)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$591.4k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-26, accession 0001493152-26-048571. Derived: 9-month figure less the 6-month figure.Report this figure(715)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$714.8k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-02, accession 0001493152-26-008564. Derived: 12-month figure less the 9-month figure.Report this figure(804)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$804.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure(518)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$518.4k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001493152-26-038482. Derived: 6-month figure less the 3-month figure.Report this figure(532)Operating cash flow, Q3 FY2026, three months to 2026-09-30−$532.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-26, accession 0001493152-26-048571. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)3.74m, Q3 FY2026
Bone Biologics Corp, shares, quarterly
Line itemUnitQ1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Diluted shares (weighted)k shares67.2Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3167,211 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0001493152-24-019271.Report this figure339Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30339,308 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-09, accession 0001493152-24-030982.Report this figure392Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30391,854 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001493152-24-046020.Report this figure661Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31660,928 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001641172-25-009746.Report this figure195Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30194,824 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001493152-25-011993.Report this figure292Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30292,321 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001493152-25-023563.Report this figure531Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31530,618 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure558Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30557,787 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure1,795Diluted shares (weighted), Q3 FY2025, three months to 2025-09-301,795,097 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure1,795Diluted shares (weighted), Q1 FY2026, three months to 2026-03-311,795,260 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001493152-26-023163.Report this figure1,797Diluted shares (weighted), Q2 FY2026, three months to 2026-06-301,796,755 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001493152-26-038482.Report this figure3,737Diluted shares (weighted), Q3 FY2026, three months to 2026-09-303,737,327 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure

Shares outstanding: 3.39mShares outstanding, period not labelled, at 2026-10-263,389,057 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-10-26, accession 0001493152-26-048571.Report this figure at Oct 26, 2026, from the cover of the 10-Q filed Oct 26, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 26, 2026, 17:12 ET. Listed shows no prices and gives no investment advice.